The Research Team of New Terrain

Dr. Shi is the chief physician of Beijing Tiantan Hospital/Tianjin Medical University General Hospital/Jing-Jin Center for Neuroinflammation. Dr. Shi is a "Yangtze River Scholar" and the chief scientist of the National Basic Research Program of China (973). Dr. Shi is committed to the diagnosis, treatment, research and translation of neuroimmune diseases. He completed his PhD., post-doctorate and clinical education at Karolinska College, The Scripps Institute, and Barrow Neurological Institute, respectively. Dr. Shi has published 220 peer-reviewed articles including Lancet, JAMA, Nature, Science, Cell sub-journals. He is the head of the neuroimmunology group of the Chinese Society of Neurology, and the chairman of the academic committee of the Pan-Asian Committee for Treatment and Research in Multiple Sclerosis (PACTRIMS), and one of the editorial board members of Science Translational Medicine.

Lei Zhang, graduated from Sun Yat-sen University, Biology. For the last 10 years, he'd been engaging in marketing and sales at KingMed Diagnostics. He's distinguished himself for continuously delivering goals, conducting thorough industrial analysis, and publishing quality research papers contributing to the establishment of domestic medical associations. He is now serving as a connector between the R&D and the market for us to speed up the turnover.

Wei-Na Jin, Bachelor of Xiangya Medical College, phD in pathophysiology of Peking Union Medical College, Postdoctor of Barrow Institute of Neurology, Associate professor of Neurology, Doctoral supervisor and National Excellent Youth. Member of neuroimmunology group of Neurology branch of Chinese Medical Association, executive director of Youth Council of China stroke society, member of translational medicine branch of China stroke society, and director of Tianjin stroke society. Dr Jin focus on immune mechanism and intervention strategy of aging related nervous system diseases through patient samples and corresponding animal models. Dr Jin has been in charge of 4 projects of National Natural Science Foundation of China; published 44 SCI articles, with representative works published in Immunity, Nat Neurosci, Stroke, etc.

In 2011, Dr. Li obtained a master's degree in biology from Nankai University and engaged in adult stem cell reprogramming and molecular cloning research. From December 2013 to December 2016, he worked as a visiting scholar of barrow Institute of Neurology in the United States, engaged in basic research training of cerebrovascular diseases and neuroimmune diseases, including multiple sclerosis, optic neuromyelitis and myasthenia gravis. From 2017 to 2020, he obtained doctor’s degree of medicine from Tianjin Medical University. At present, his research contents include the development of new drugs for the treatment of nervous system diseases, the development of diagnostic reagents and transformation applications. Some of his research achievements were published in Science Translational Medicine, Journal of experimental medicine, Proceedings of the National Academy of Sciences and Lancet Neurology, etc., and he won 3 Chinese invention patents and 1 International PCT invention patent.

Minshu Li, PhD, the associated researcher at Tianjin Medical University General Hospital. From 2013-2015, she finished scientific research training at The Neuroimmunology Department of the Barrow Neurology Institute in the USA. The primary research goal is about the laboratory diagnosis of neuroimmune diseases, and she is committed to the investigation and development of laboratory-associated diagnosis technology based on Cell Based Assay (CBA) system for the detection of the autoantibodies in the neurological disease. She participated in the program that edited and supported the revision of “Neuroimmune Laboratory”, the textbook of resident doctor standardized training. By now, as the first author or corresponding author, there are 31 SCI papers that have been published in multiple scientific journals with a cumulative impact factor of 150.8, such as Proc Natl Acad Sci U S A., FASEB J., J Cereb Blood Flow Metab., Front. Immunol. Aging and Disease, etc. In addition, she also hosted a program of the National Natural Science Foundation of China, and participated in execution the National “973 Program”.

Chao Zhang, PhD, Associate Professor, Associate Chief Physician, Master's Supervisor. He is a recipient of the Tianjin Science Fund for Distinguished Young Scholars. He is currently a committee member of the Electromyography and Clinical Neurophysiology Group of the Chinese Medical Association Neurology Branch, a leader of the Neuroimmunology Group and a committee member of the Neuromyopathy Group of the Tianjin Medical Association Neurology Branch. He has long been engaged in scientific research and clinical treatment of autoimmune diseases of the nervous system. As one of the principal investigators, he found that Tolimumab, an IL-6 receptor blocker, has significant advantages over Azathioprine in reducing the relapse rate and disability rate in patients with neuromyelitis optica spectrum disorders, providing Class I evidence-based medical evidence for the treatment of this disease. We have also proposed the first important type I interferon-related pathogenesis by single-cell transcriptome sequencing. He has published 17 SCI articles as first author or corresponding author in internationally renowned journals such as The Lancet Neurology, JAMA Neurology, Neurology-Neuroimmunology and Neuroinflammation, and Frontiers in Immunology.

Jingshan Chen，PhD. student at Tianjin Medical University major in Neurology. He used to work in Tianjin Medical University General Hospital. He leads the development of new biomarkers for neurological diseases based on the ultra-sensitive single-molecule immune array (Simoa) platform. He mainly studies basic and clinical research on neurological diseases such as ischemic stroke, intracerebral hemorrhage, and myasthenia gravis. He has published 10 peer-reviewed articles including The Lancet Regional Health.

Zheng Pei, MD. technical director of r&d Department in Tianjin New Terrain Biotechnology Co.,Ltd Dr. Zheng graduated from Tianjin Medical University. From 2016 to 2019, she completed standardized clinical training for resident physicians. The main research is focus on new markers for diagnosis and curative effect prediction of cerebrovascular and autoimmune diseases of the nervous system. She is responsible for the technology upgrade and optimization of auto-antibody detection. She has published several SCI articles and participated in National nature and science foundation.

Wei Changjuan, PhD, lecturer, deputy chief physician. She graduated from Tianjin Medical University in 2009 with a master's degree in clinical medicine and a doctor's degree in 2015. Since taking office, she has been committed to the communication and coordination of the research and development team, and has certain working experience in the protection of intellectual property rights.

Hao Li, MFA ,manager of the operation department of Tianjin New Terrain Biotechnology Co., Ltd., studied at Shandong Normal University from 2011 to 2018, obtained a bachelor's degree and a master's degree in education, and worked as a teacher in Jinan from 2018 to 2021. During his teaching period, he won the first prize of teaching in Shizhong District, Jinan City. Joined Tianhai Xinyu in February 2021, participated in HRTP-performance compensation manager training in November, and passed the training assessment.

Kaibin Shi, PhD in Neurology from Tianjin Medical University and Postdoctoral Fellow at Barrow Neurology Institute, St. Joseph's Hospital and Medical Center. He is under the supervision of Professor Fudong Shi, a renowned neuroimmunologist. His main research interests are the occurrence and evolution of neuroinflammation after acute brain injury and the exploration of novel immune intervention therapies for neurological diseases. His main research work has been published in Lancet Neurology, Circulation Research, JAMA Neurology, Science Translational Medicine, Nature Neuroscience, Immunity, etc. As a team member, he was awarded the first prize of Tianjin He has been awarded the First Prize of Natural Science in Tianjin, the China Stroke Association 2021 Youth Innovation Award, and the title of Young Outstanding Scientific and Technological Talent in Tianjin Innovative Talent Promotion Program.

Jiang Wei, graduated from Tianjin Medical University, majoring in neurology. Since 2017, I have been working in the Department of Neurology of Tianjin Medical University General Hospital as a resident physician and lecturer. During this period, I have completed standardized resident training. From 2020 to 2021, I have served as the chief resident physician in the Department of Neurology. From October 2013 to July 2015, I was in the University of Moncton and New Brunswick Medical Center for visiting doctoral research, and won a New Brunswick scholarship of $55000CAD to conduct cooperative research on the mechanism of cholinergic anti-inflammatory system in central nervous system autoimmune diseases. SCI papers published as first/co-first author in PNAS (IF:11.2), Genome Medicine (IF:11.1), Theranostics (IF:11.5), Journal of Immunology (IF:5.4). Other work was published in the journal of Frontiers in Cellular Neuroscience, Frontiers in Genetics, BMC Neurol as the corresponding author, and co-published SCI papers in the Journal of Immunology. Frontiers in Immunology, J Chromatogr B Analyt Technol Biomed Life Sci et al. In 2018, I was awarded the "Outstanding Nova" project of Tianjin Medical University General Hospital. I also undertook the General Project of National Natural Science Foundation of China (2022), The Youth Project of National Natural Science Foundation of China (2019), the Youth Project of Tianjin Natural Science Foundation of China (2019), and was selected into the "Tianjin University Youth Reserve Talent Support Program" (2020).